期刊
CHEMMEDCHEM
卷 16, 期 6, 页码 932-941出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.202000833
关键词
anticancer agents; bioimaging; heterometallic; metallodrugs; theranosis
资金
- AEI (Ministerio de Ciencia Innovacion y Universidades) [PID2019-104379RB-C21, RTI2018-097836-J-I00, RYC2018-025872, RED2018-102471-T]
- Gobierno de Aragon-Fondo Social Europeo [E07_20R]
- Gobierno de Aragon
Heterometallic drugs offer enhanced therapeutic potential through careful selection of different metallic fragments, as well as the incorporation of traceability features. The integration of traceability and therapy in one system, known as theranostic agents, is particularly important in cancer research. The well-established therapeutic potential of Pt-II-, Ru-II- and Au-I-based drugs, combined with the outstanding optical properties of d(6) transition metal complexes, allow for the development of traceable metallodrugs that can be fine-tuned for a new generation of drugs.
Heterometallic drugs are emerging as a great alternative to conventional metallodrugs. Careful selection of different metallic fragments makes possible to enhance not only the therapeutic potential by a synergistic effect, but also to incorpore key features like traceability. Drugs that integrate traceability and therapy in one system are known as theranostic agents. In cancer research, theranostic agents are becoming increasingly important. They deliver crucial information regarding their biological interplay that can ultimately be used for optimization. The well-established therapeutic potential of Pt-II-, Ru-II- and Au-I-based drugs combined with the outstanding optical properties of d(6) transition metal complexes grant the delivery of traceable metallodrugs. These species can be easily fine-tuned through modification of their respective ligands to provide a new generation of drugs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据